顺铂联合放疗治疗中晚期食管癌预后分析.docVIP

顺铂联合放疗治疗中晚期食管癌预后分析.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
顺铂联合放疗治疗中晚期食管癌预后分析   [摘要] 目的 重点研究和探讨顺铂联合放疗治疗中晚期食管癌患者的临床疗效及安全性。 方法 回顾性分析我院2010年1月1日~2012年12月31日期间收治的60例中晚期食管癌患者的临床资料。将患者随机分为两组,对照组总计30例应用放疗进行治疗;观察组总计30例在对照组的治疗基础上加用顺铂联合治疗。然后将两组数据结果进行分析,分析探讨两组患者疗效、患者满意率以及不良反应的结果。 结果 通过对我院收治的60例中晚期食管癌患者的临床资料进行分析,观察组患者的治疗效果、患者满意率、不良反应均显著好于对照组(P0.05)。 结论 顺铂联合放疗治疗中晚期食管癌患者具有很好的临床疗效,并且具有良好的安全性,目前已经成为治疗中晚期食管癌患者的主要方法,对我国治疗中晚期食管癌的发展具有重要价值。   [关键词] 顺铂;放疗;中晚期食管癌;预后分析   [中图分类号] R735.1 [文献标识码] B [文章编号] 2095-0616(2013)24-215-02   Analysis on prognosis of moderate and advanced esophageal carcinoma by cisplatin combined with radiotherapy   BA Yanhua   Department of Radiation, Zhengzhou Peoples Hospital, Zhengzhou 450003   [Abstract] Objective To focus on and explore the clinical efficacy and safety of cisplatin combined with radiotherapy in the treatment of patients with moderate and advanced esophageal carcinoma. Methods The clinical data of 60 patients with moderate and advanced esophageal carcinoma who were treated in our hospital from January 1, 2010 to December 31, 2012 were studied and compared by using the retrospective analysis method. All patients were randomly divided into the two groups, 30 cases of the control group were given radiotherapy, while 30 cases of the observation group were treated with cisplatin based on the use of radiotherapy. Then the efficacy, patients satisfaction rate and adverse reactions of patients in the two groups were analyzed and explored. Results The analysis of clinical data of 60 patients with moderate and advanced esophageal carcinoma treated in our hospital showed that the efficacy, patients satisfaction rate and adverse reactions of patients in the observation group were significantly better than those in the control group(P0.05). Conclusion Cisplatin combined with radiotherapy in the treatment of patients with moderate and advanced esophageal carcinoma has good clinical efficacy, good security, and has become the main treatment method for patients with moderate and advanced esophageal carcinoma now,

文档评论(0)

you-you + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档